Clinuvel Pharmaceuticals (ASX:CUV) appointed specialty pharmaceutical firm Diligens Salud, part of the Scienza Group, to market and sell the Scenesse (afamelanotide) therapy in Argentina, according to a Friday filing with the Australian bourse.
The therapy, used to treat patients with erythropoietic protoporphyria, will be facilitated under maned-patient programs, with both parties collaborating on long-term formal marketing authorization, the filing said.
Erythropoietic protoporphyria is a genetic condition characterized by skin sensitivity to sunlight and artificial light.
The company's shares were up almost 1% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.